Svelte Medical Systems pulled in $22 million in new financing to help finish a pivotal clinical study and prepare for the European commercialization of two balloon-expandable coronary stent systems in early 2015.
California's Thoratec grew revenue in its 2013 third quarter, thanks largely to the company's HeartMate pumps. But the product line's rapid sales climb may be slowing.
Elixir Medical notched more promising results for its DESolve device, keeping vessels clear with low rates of adverse events, and those data should help it contend with global giant Abbott Laboratories in the market for bioresorbable stents.
Molecular diagnostics company Veracyte pulled the trigger and finally hit the public markets on Oct. 30, and the South San Francisco company's stock experienced some slight first-day gains. It closed at $13.25, up nearly 2%.
An international clinical trial concluded that using a two-stent technique to treat coronary bifurcation lesions with a large stenotic side branch didn't work any better than a provisional stenting approach.
Teleflex will snatch up Texas-based Vidacare for $262.5 million to add that company's inside-the-bone/vascular access devices to its own product roster.
As studies and controversies mount over coronary stent overuse, the American College of Cardiology has entered the debate by softening the language it uses in published treatment guidelines. Stent manufacturers will want to watch closely how well the changes play out over the coming year.
Washington's Kona Medical is pressing forward with its novel approach to renal denervation, releasing solid data as it develops a non-invasive device to lower blood pressure in patients with drug-resistant hypertension.
Devicemaker CVRx has hauled in another $12 million to add to its Series F financing, giving it vital cash to keep the clinical trial engine running for its hypertension treatment device and boost international marketing efforts.
Medtronic is moving up its expected U.S. launch date for CoreValve, posting impressive safety and efficacy results as it looks to contend with market leader Edwards Lifesciences on its home turf.
The private equity firm Juniper has completed its $68.3 million purchase of Theragenics, a struggling Georgia maker of surgical tools and prostate cancer treatments.
Volcano said it expects 2013 third-quarter revenue to inch moderately higher. But investors wanted far more, and they punished the San Diego device company for setting diminished expectations.
St. Jude Medical is celebrating promising early international data from its Portico transcatheter aortic heart valve, showing that most patients with the implant experienced major benefits after a month.
Edwards Lifesciences remains atop the synthetic heart valve scrum, but the company's tepid growth projections have alarmed investors, and Edwards' shares fell almost 10% on Tuesday as it again forecasted earnings below expectations.
Allergan will sell its obesity intervention business to Apollo Endosurgery, a 2012 Fierce 15 winner, in a deal worth up to $110 million, capping its yearlong quest to unload the Lap-Band and other related devices.
The U.S. Department of Defense is launching a $70 million project involving the use of a brain monitoring implant to help soldiers better manage depression, stress and other related conditions.
Covidien is lightening its stake in the medical sealant market, agreeing to sell its Confluent Surgical product line to Integra LifeSciences for $235 million as it cuts costs and refocuses on high-growth spaces.
South Korea's government is revving up regional exports of medical equipment, boosting the competitive pressures for device companies in Asia.
Boston Scientific, the latest entrant into the transcatheter valve replacement space, has won a CE mark for its Lotus implant, nudging the company into an overseas market headlined by squabbles between Edwards Lifesciences and Medtronic.
Haemonetics reported healthy gains in revenue and net income during its fiscal 2014 second quarter. The Massachusetts maker of blood management devices and related technology credited a big acquisition plus general reorganization and "expense management" with driving improvement even as the overall market has suffered.